EU approves Gilenya for paediatric MS
European regulators have approved Novartis’ Gilenya for the treatment of children and adolescents from 10 to 17 years old with relapsing-remitting forms of multiple sclerosis (RRMS).
Read More
Tag: fingolimod
FDA approves Novartis’ Gilenya for paediatric use
US regulators have approved Novartis’ Gilenya to treat children and adolescents with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for this patient group.
Read More
Novartis’ Gilenya hits targets in paediatric MS trial
Novartis has released top-line data showing that Gilenya significantly reduced relapses in children and adolescents with multiple sclerosis.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
